Morepen Laboratories (MORE IN): Strong Performance in FY24; Positive Momentum to Sustain
Morepen Laboratories achieved impressive revenue, EBITDA, and PAT growth in FY24, driven by medical devices and API businesses. Increasing...
Profit from India's Rapidly Growing Biotechnology Industry
Now is a strategic time to focus on the upside potential of biotechnology companies in India, as India’s biotechnology industry is projected to...
India's Budgets: 2006-2015. Key Charts, and Key questions
In continuation of my work of detailed work on India Budget for last ten years, this piece through simple charts puts in perspective: 2014 Actual...
No more insights